Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted

Edgewise Therapeutics, Inc.

2025-Q1 EPS reported -$0.43

Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.
Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.
Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.
Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.